Aura Biosciences, Inc. Operating Cash Flow
Aura Biosciences, Inc. (AURA) reported Operating Cash Flow of -$62.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.50M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$29.89M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$20.47M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$20.14M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$84.74M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$79.81M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$63.85M.
- Aura Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$54.60M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$62.39M 10-Q · filed 2026-08-11 | -$82.86M derived: sum of 3 quarters · filed 2026-08-11 | -$103.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$29.89M 10-Q · filed 2026-05-11 | -$50.36M derived: sum of 2 quarters · filed 2026-05-11 | -$70.51M derived: sum of 3 quarters · filed 2026-05-11 | -$91.28M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$20.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$40.61M derived: sum of 2 quarters · filed 2026-03-30 | -$61.39M derived: sum of 3 quarters · filed 2026-08-11 | -$84.74M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$20.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$40.92M derived: sum of 2 quarters · filed 2026-08-11 | -$64.27M 10-Q · filed 2025-11-13 | -$88.22M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$20.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$44.13M 10-Q · filed 2026-08-11 | -$68.08M derived: sum of 3 quarters · filed 2026-08-11 | -$83.35M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$23.36M 10-Q · filed 2026-05-11 | -$47.31M derived: sum of 2 quarters · filed 2026-05-11 | -$62.58M derived: sum of 3 quarters · filed 2026-05-11 | -$78.71M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$23.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$39.23M derived: sum of 2 quarters · filed 2026-03-30 | -$55.35M derived: sum of 3 quarters · filed 2026-03-30 | -$79.81M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$15.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$31.40M derived: sum of 2 quarters · filed 2025-11-13 | -$55.85M 10-Q · filed 2025-11-13 | -$73.24M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$16.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$40.58M 10-Q · filed 2025-08-13 | -$57.97M derived: sum of 3 quarters · filed 2025-08-13 | -$73.37M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$24.45M 10-Q · filed 2025-05-15 | -$41.84M derived: sum of 2 quarters · filed 2025-05-15 | -$57.24M derived: sum of 3 quarters · filed 2025-05-15 | -$71.89M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$32.79M derived: sum of 2 quarters · filed 2025-03-24 | -$47.44M derived: sum of 3 quarters · filed 2025-03-24 | -$63.85M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$15.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$30.05M derived: sum of 2 quarters · filed 2024-11-12 | -$46.46M 10-Q · filed 2024-11-12 | -$64.47M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$14.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$31.06M 10-Q · filed 2024-08-08 | -$49.07M derived: sum of 3 quarters · filed 2024-08-08 | -$59.83M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$16.41M 10-Q · filed 2024-05-09 | -$34.42M derived: sum of 2 quarters · filed 2024-05-09 | -$45.19M derived: sum of 3 quarters · filed 2024-05-09 | -$55.81M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$18.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$28.77M derived: sum of 2 quarters · filed 2024-03-27 | -$39.40M derived: sum of 3 quarters · filed 2024-03-27 | -$54.60M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$10.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$21.39M derived: sum of 2 quarters · filed 2023-11-09 | -$36.59M 10-Q · filed 2023-11-09 | -$48.67M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$10.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$25.83M 10-Q · filed 2023-08-09 | -$37.91M derived: sum of 3 quarters · filed 2023-08-09 | -$46.60M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$15.20M 10-Q · filed 2023-05-11 | -$27.29M derived: sum of 2 quarters · filed 2023-05-11 | -$35.98M derived: sum of 3 quarters · filed 2023-05-11 | -$42.47M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$20.78M derived: sum of 2 quarters · filed 2023-03-15 | -$27.27M derived: sum of 3 quarters · filed 2023-03-15 | -$32.41M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$8.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$15.19M derived: sum of 2 quarters · filed 2022-11-10 | -$20.32M 10-Q · filed 2022-11-10 | -$24.08M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$11.63M 10-Q · filed 2022-08-11 | -$15.39M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$5.14M 10-Q · filed 2022-05-12 | -$8.89M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$3.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$24.32M 10-K · filed 2022-03-23 | ||
| 2020-09-30 | -$20.56M 10-Q · filed 2021-11-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |